Zenas Biopharma Inc
NASDAQ:ZBIO
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
16.92
25.68
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ZBIO stock under the Base Case scenario is 12.938 USD. Compared to the current market price of 19.845 USD, Zenas Biopharma Inc is Overvalued by 35%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Zenas Biopharma Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ZBIO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Zenas Biopharma Inc
Balance Sheet Decomposition
Zenas Biopharma Inc
Current Assets | 188.6m |
Cash & Short-Term Investments | 183.9m |
Other Current Assets | 4.7m |
Non-Current Assets | 11.4m |
PP&E | 706k |
Other Non-Current Assets | 10.6m |
Current Liabilities | 39.1m |
Accounts Payable | 8.4m |
Accrued Liabilities | 29.8m |
Other Current Liabilities | 939k |
Non-Current Liabilities | 14k |
Other Non-Current Liabilities | 14k |
Earnings Waterfall
Zenas Biopharma Inc
Revenue
|
50m
USD
|
Operating Expenses
|
-106.4m
USD
|
Operating Income
|
-56.4m
USD
|
Other Expenses
|
1.7m
USD
|
Net Income
|
-54.8m
USD
|
Free Cash Flow Analysis
Zenas Biopharma Inc
USD | |
Free Cash Flow | USD |
ZBIO Profitability Score
Profitability Due Diligence
Zenas Biopharma Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Zenas Biopharma Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
ZBIO Solvency Score
Solvency Due Diligence
Zenas Biopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Zenas Biopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZBIO Price Targets Summary
Zenas Biopharma Inc
According to Wall Street analysts, the average 1-year price target for ZBIO is 37.485 USD with a low forecast of 27.27 USD and a high forecast of 47.25 USD.
Dividends
Current shareholder yield for ZBIO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zenas Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waltham, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2024-09-13. Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is focused on the development and commercialization of immunology-based therapies for patients in need. Its lead immunology and inflammation (I&I) product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The company is developing obexelimab as a potential I&I franchise for patients in several autoimmune diseases. Its pipeline also includes two global programs, ZB002 (an anti-TNFα monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion), and two regional programs, ZB001 (also known as VRDN-001, an IGF-1R monoclonal antibody), and related programs, and ZB005 (also known as DNTH103, an anti-active C1s monoclonal antibody), for which the Company hold the development and commercialization rights in greater China.
Contact
IPO
Employees
Officers
The intrinsic value of one ZBIO stock under the Base Case scenario is 12.938 USD.
Compared to the current market price of 19.845 USD, Zenas Biopharma Inc is Overvalued by 35%.